DEVELOPING A REGIONAL CANCER CENTER IN SOUTH CAROLINA

南卡罗来纳医科大学(MUSC)希望 发展综合性癌症中心--霍林斯肿瘤学中心 (HOC)以降低其所在地区的癌症发病率和死亡率。MUSC是 为实现这一目标进行重大投资，建造一座新楼 致力于癌症研究以及翻新更多的医院区域 治疗癌症。MUSC的整个管理结构致力于 无论是在学术方面还是在基础设施发展方面，这种积累都是如此。 据统计，南卡罗来纳州领先或几乎领先于各州 六种重要癌症的死亡率。该地区呈现出一种 对服务不足和少数群体产生影响的非同寻常的机会 人口。外展和预防是其主要组成部分 可以实现特定的目标。这些措施包括：1)扩展 早期的区域性SEER相容肿瘤登记到整个 地理区域；2)在初级预防方面与 三叉戟地区卫生区和国务院。卫生与公众服务部 环境控制；3)与已证实的少数族裔开展外展活动 组织；4)大量少数族裔患者的进入和 合作组试验；5)扩大乳房早期筛查和 宫颈癌对未得到充分服务的人群的影响 服务通过HOC进行跟进；6)发起适当的咨询和 以预防为导向的职业教育。 该机构的目标是在#年扩大其癌症研究基地。 基础科学和临床领域，特别强调以下领域 翻译多学科方法。一家中心的招聘 伴随着一个主要研究小组的主任进入了最后阶段。 5个部门主席空缺职位优先用于 各种癌症特定学科或相关学科。研究计划是为了 将在基础分子和生物化学领域发起和规划。近期 MUSC在干细胞生物学方面的进展具有独一无二的挑衅性 骨髓移植和基因治疗的新机遇。 包括单链和单链在内的尖端单抗技术 免疫毒素将被整合到临床试验中。这两个都是 活动涉及与四大NCI的持续或初期合作 实验室负责人。 必须探索最优治理模式，以实现最终的行政管理 HOC的身份。的具体权限和特权的计划 主任正在讨论中，包括中心和 南加州大学所有其他与癌症相关的项目。在所有新程序开发中， 目标是组织三个工作组，由内部和 区域规划者，拥有关键的外部咨询专家和其他 顾问。一个重要的金融基础的集会正在计划中 为了成功地启动和发展作为第一名的HOC 商定了南加州大学整个行政结构的优先次序。 致力于MUSC的几个独特的计划机会正在成为目标 癌症活动。

The Medical University of South Carolina (MUSC) wishes to plan for the development of a comprehensive cancer center, Hollings Oncology Center (HOC) to reduce the morbidity and mortality of cancer in its area. MUSC is making a major investment towards this goal by constructing a new building devoted to cancer research as well as renovating additional hospital areas for cancer. The entire administrative structure of MUSC is committed to this build-up both in academic terms and in infrastructure development. Statistically, South Carolina leads or almost leads the states in the mortality of six significant cancers. This region presents an extraordinary opportunity to make an impact on underserved and minority populations. Outreach and prevention are major components by which specific objectives can be realized. These include: 1) an extension of the incipient regional SEER-compatible tumor registry to the entire geographic area; 2) coalition and programs in primary prevention with the regional Trident Health District and State Dept. of Health and Environmental Control; 3) outreach activities with proven minority organization; 4) entering of substantial numbers of minority patients and cooperative group trials; 5) expanding early screening for breast and cervical cancer to underserved populations with integration into full- service follow through via HOC; 6) initiating appropriate consultation and prevention-oriented professional education. The institution has the goal of increasing its cancer research base in basic science and clinical areas, with particular stress in the areas of translational multidisciplinary approaches. Recruitment for a center director concomitant with a major research group is into final stages. Five vacant department chair positions are targeted preferentially for various cancer specific or related disciplines. Research programs are to be initiated and planned in basic molecular and biochemical areas. Recent advances at MUSC in stem cell biology are uniquely provocative to develop novel opportunities in bone marrow transplantation and gene therapy. Cutting edge monoclonal antibody technology including single chains and immunotoxins are to be integrated into clinical trials. Both of these activities involve ongoing or incipient collaborations with four major NCI laboratory chiefs. Optimal governance models have to be explored for the final administrative identity of HOC. Plans for specific authorities and prerogatives for the director are being discussed including the interface between the center and all other cancer-related programs at MUSC. In all new program development, the goal is to organize three working groups comprised of internal and regional planners with key external advisory experts and additional consultants. An assembly of a significant financial base is being planned for successful start-up and development of the HOC which is the number one agreed-upon priority of the entire administrative structure at MUSC. Several unique program opportunities dedicated to MUSC are being targeted to cancer activities.